News articles for BioMedReports:
Wednesday, May 8, 2013
Imprimis Rising: Unique Pathway Requires Fewer and Smaller Clinical Trials
LOS ANGELES, CA -- (Marketwired) -- 05/08/13 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the best performing stocks in the biotech industry ... read more
Tuesday, May 7, 2013
Tauriga Sciences' CEO Pulls Off Impressive Turnaround; More to Come?
LOS ANGELES, CA -- (Marketwired) -- 05/07/13 -- When Tauriga Sciences, Inc. (OTCQB: TAUG) CEO, Seth Shaw, took the job in August of 2012 his mission was to advance an underperforming company that held licensing rights to a promising immunotherapeutic drug for cancer patients. Tauriga was called Immunovative, Inc. ... read more
Wednesday, April 24, 2013
Monday, April 22, 2013
Thursday, April 4, 2013
CEL-SCI's Price Rebound Looks Strong
LOS ANGELES, CA -- (Marketwired) -- 04/04/13 -- Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released by CEL-SCI (NYSE Amex: CVM) earlier this ... read more
Thursday, March 14, 2013
AntriaBio Set for a Major Short Squeeze
LOS ANGELES, CA -- (Marketwire) -- 03/14/13 -- A handful of early investors are fighting an uphill battle after investing in shares of AntriaBio (OTCBB: ANTB), which recently swooped in to snag an intriguing lead diabetes product, AB101, after a private firm had already invested more than $100 million ... read more
Tuesday, February 19, 2013
Wednesday, February 6, 2013
Three Upcoming Biopharma Catalyst Trades to Consider
LOS ANGELES, CA -- (Marketwire) -- 02/06/13 -- While trading catalyst driven small cap biotechs can be risky, if executed with discipline and closely monitored technical chart analysis, these types of trades can offer rewarding returns to investors.
Along with the rest of the market, a few of our recent ... read more
Tuesday, January 29, 2013
EnteroMedics' Late Stage Treatment Takes on Obesity Epidemic
LOS ANGELES, CA -- (Marketwire) -- 01/29/13 -- Our focus turns to EnteroMedics, which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight.
EnteroMedics' approach may be a better solution for people who see little or no benefit from current ... read more
Tuesday, January 22, 2013
Athersys: Short Term Catalyst With Long Term Potential
LOS ANGELES, CA -- (Marketwire) -- 01/22/13 -- In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward.
Last July, we first wrote about Pluristem Therapeutics (NASDAQ: PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products ... read more
Tuesday, January 15, 2013
Closer Look: BioLineRx's Multi Billion Dollar Schizophrenia Drug
LOS ANGELES, CA -- (Marketwire) -- 01/15/13 -- BioLineRx engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in class ... read more
Wednesday, December 19, 2012
Smart Investors Spot Profitable Upside in Neptune's Recovery Plan
LOS ANGELES, CA -- (Marketwire) -- 12/19/12 -- Neptune Technologies & Bioresources, Inc. (NASDAQ: NEPT) has seen its stock fall 45% from its closing price on November 7th. On December 8th, Neptune suffered a tragedy, in which their manufacturing facility and inventory were completely destroyed in an explosion that ... read more
Thursday, September 6, 2012
Thursday, April 19, 2012
Tuesday, April 17, 2012
Monday, April 9, 2012
Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
LOS ANGELES, CA -- (Marketwire) -- 04/09/12 -- Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere.
In an exclusive interview, Timothy Mayleben, who has served ... read more
Wednesday, April 4, 2012
Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming
LOS ANGELES, CA -- (Marketwire) -- 04/04/12 -- Trading on the Euronext, Pharming Group NV (EURONEXT: PHARM) produces, purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rejection, Blood Coagulation Disorders and Ischemic Reperfusion Injury.
Pharming Group develops products for ... read more
Tuesday, March 6, 2012
Exact Sciences' Colorectal Cancer Test Could Have Big Impact, Says CEO
LOS ANGELES, CA -- (Marketwire) -- 03/06/12 -- Exact Sciences Corporation (NASDAQ: EXAS), the molecular diagnostics company focused on colorectal cancer, has been steadily inching towards their commercialization goals and one need only look at their stock chart to see the steady, reliable advancement.
In fact, inch by inch, ... read more